Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

摘要: The aim of the study was to evaluate association vascular endothelial growth factor (VEGF) genotypes with treatment efficacy in a randomized trial. This compared two chemotherapy regimens (FOLFIRI versus XELIRI) combined bevacizumab, as first-line for metastatic colorectal cancer. DNA extracted from blood samples 173 patients participating Genotyping performed selected SNPs (VEGF−1154, +936, −634, −2578 and −1498). All candidate were evaluated associations overall survival (OS), progression-free (PFS) response rate (RR). There no significant differences respect distribution groups. VEGF−1154 GG genotype more frequent not responding responders (65.5 39.8%, P=0.032). Furthermore, associated inferior median OS GA (hazards ratio=1.68; 95% confidence interval: 1.10–2.57; P=0.016) or alternative (GA AA) ratio=1.62; 1.09–2.40; P=0.017). In multivariate analysis, remained adverse OS. Our results support potential predictive ability VEGF cancer receiving irinotecan-based plus terms RR However, current should be validated prospectively, larger cohorts.